Scarica l'app Stockscreener
12.96
1.82%
-0.24
Precedente Chiudi:
$13.20
Aprire:
$13.192
Volume 24 ore:
1.50M
Relative Volume:
0.90
Capitalizzazione di mercato:
$4.07B
Reddito:
$2.68B
Utile/perdita netta:
$-184.45M
Rapporto P/E:
-19.04
EPS:
-0.6805
Flusso di cassa netto:
$229.23M
1 W Prestazione:
+2.37%
1M Prestazione:
+8.27%
6M Prestazione:
+55.58%
1 anno Prestazione:
+60.79%
Intervallo 1D:
$12.93
$13.31
Intervallo di 1 settimana:
$12.33
$13.48
Portata 52W:
$6.685
$13.48
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Confronta AMRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.96 | 4.15B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
127.17 | 55.90B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.31 | 51.72B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.91 | 44.71B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.01 | 37.30B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
45.79 | 20.48B | 0 | -5.87M | -767.30K | -0.45 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-02-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
| 2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-27 | Iniziato | Goldman | Sell |
| 2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
| 2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Downgrade | SunTrust | Buy → Hold |
| 2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Iniziato | Morgan Stanley | Overweight |
| 2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Is Amneal Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Volume & Long Hold Capital Preservation Tips - ulpravda.ru
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance - PharmiWeb.com
A Look At Amneal Pharmaceuticals (AMRX) Valuation As Analyst Optimism And Revenue Outlook Support Recent Momentum - Sahm
KeifeRx and Amneal partner on Parkinson’s disease drug development By Investing.com - Investing.com Canada
KeifeRX announces research collaboration & option agreement with Amneal Pharmaceuticals - MarketScreener
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson’s Disease - Business Wire
Will Amneal Pharmaceuticals Inc. stock recover faster than peersRecovery Day Options & how to pick the right width - ulpravda.ru
Can Amneal Pharmaceuticals Inc. stock continue upward trendJuly 2025 Closing Moves & Breakout Confirmation Trade Signals - ulpravda.ru
Why Amneal Pharmaceuticals Inc. stock remains a top recommendationMarket Risk Summary & Breakout Confirmation Trade Signals - ulpravda.ru
Smart Money: Will Amneal Pharmaceuticals Inc. stock benefit from upcoming earnings reportsEarnings Miss & AI Enhanced Market Trend Forecasts - ulpravda.ru
Will Amneal Pharmaceuticals Inc. stock benefit from upcoming earnings reports2025 Price Momentum & Growth Oriented Trading Recommendations - ulpravda.ru
Is Amneal Pharmaceuticals Inc. stock vulnerable to regulatory risksTrade Risk Summary & Weekly Market Pulse Alerts - ulpravda.ru
What is the fair value of Amneal Pharmaceuticals Inc. stock nowFinancial Sector Performance & Superior Trading Portfolio - ulpravda.ru
Can This Healthcare Stock Keep Going After a Nearly 70% Surge? - Barchart.com
Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Unveiling a 10% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month HighShould You Buy? - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $13.04 By Investing.com - Investing.com Canada
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Shareholder Returns - Yahoo Finance
Allspring Global Investments Holdings LLC Boosts Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
How Recent Q3 Beats And FDA Wins Are Shaping The Amneal Pharmaceuticals (AMRX) Story - Yahoo Finance
Latest FDA Denosumab Decisions Offer Mixed Verdicts - Citeline News & Insights
Suboxone Market is Going to Booming Growth 2025 With Top Key - openPR.com
Amneal Launches Complex Generic Fluorometho-lone Ophthalmic Suspension - Specialty Pharmacy Continuum
Amneal Pharma-mAbxience gets USFDA approval for Boncresa, Oziltus - Medical Dialogues
Amneal Pharmaceuticals stock hits 52-week high at $12.99 By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals stock hits 52-week high at $12.99 - Investing.com
How Amneal Pharmaceuticals Inc. stock trades during market volatilityDividend Yield Trends & Join a Community of Smart Investors - Bollywood Helpline
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Short Squeeze: Why Amneal Pharmaceuticals Inc stock remains a top recommendation2025 Key Highlights & Community Verified Watchlist Alerts - moha.gov.vn
FDA approves Amneal’s two denosumab biosimilars for US market By Investing.com - Investing.com Nigeria
Amneal stock rises after FDA approves two denosumab biosimilars By Investing.com - Investing.com Australia
Amneal Reports FDA Approval of Denosumab Biosimilars - marketscreener.com
Amneal stock rises after FDA approves two denosumab biosimilars - Investing.com
FDA approves Amneal’s two denosumab biosimilars for US market - Investing.com
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® - The Manila Times
Amneal Pharmaceuticals (AMRX): Valuation Check After FDA Approval for New Epinephrine Injection - Sahm
Assenagon Asset Management S.A. Raises Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Market Leaders: What insider trading reveals about Amneal Pharmaceuticals Inc. stockJuly 2025 Momentum & High Return Stock Watch Alerts - Улправда
What insider trading reveals about Amneal Pharmaceuticals Inc. stockJuly 2025 Setups & Free Low Drawdown Momentum Trade Ideas - Улправда
Operating cash flow per share of Amneal Pharmaceuticals, Inc. Class A – DUS:2DT - TradingView — Track All Markets
Amneal Pharmaceuticals stock hits 52-week high at $12.69 By Investing.com - Investing.com Australia
Aug Patterns: Why Amneal Pharmaceuticals Inc. stock attracts global investorsJuly 2025 Volume & Long Hold Capital Preservation Tips - ulpravda.ru
Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 52-Week HighStill a Buy? - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $12.69 - Investing.com
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.37%
1.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):